NCT01037023已完成不适用
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Occurrence of adverse events after Topotecan administration
研究概览
简要总结
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
详细描述
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
Topotecan will be administered as described the prescribing information or by physician's decision.
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Patients administrated Topotecan
There is only one group. This group includes patients administrated Topotecan
干预措施: Topotecan (Drug)
结局指标
主要结局
Occurrence of adverse events after Topotecan administration
时间窗: 9 months
次要结局
- Occurrence of unexpected adverse event or adverse drug reaction(9 months)
- Occurrence of serious adverse event or adverse drug reation(9 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Regulatory AVAMYS Nasal Spray PMSRhinitis, Allergic, Perennial and SeasonalNCT01001130GlaxoSmithKline3,244
已完成
不适用
Regulatory TYKERB® Tablets PMSCancerNCT00975988GlaxoSmithKline750
已完成
不适用
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010Diabetes Mellitus, Type 2NCT01294553GlaxoSmithKline717
已完成
不适用
AVODART(Dutasteride) Post-marketing Surveillance(PMS)Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT01299571GlaxoSmithKline3,977
已完成
不适用
Regulatory Nebilet PMSHypertensionHeart FailureNCT01077661GlaxoSmithKline743